Navigation Links
Heska Announces Installation of New Chemistry Analyzer
Date:12/14/2009

LOVELAND, Colo., Dec. 14 /PRNewswire-FirstCall/ -- Heska Corporation (Nasdaq: HSKA; "Heska" or the "Company"), a leading provider of veterinary diagnostic and specialty products, today announced the first customer installation of the Company's new DRI-CHEM® 7000 Veterinary Chemistry Analyzer (the "DRI-CHEM® 7000").

(Logo: http://www.newscom.com/cgi-bin/prnh/20000622/HESKALOGO)

Customers receiving these analyzers have invested in the fastest multi-patient clinical chemistry analyzer available to the veterinary in-clinic market. The DRI-CHEM® 7000 analyzer provides the same testing flexibility of the DRI-CHEM® 4000 Veterinary Chemistry Analyzer plus additional advantages such as multiple-patient staging, auto-dilution and a new "STAT" sample feature which provides emergency sample flexibility in critical cases.

"We are pleased to deliver another choice for advanced chemistry analyzers to the veterinary market and believe this latest addition will continue to support our customers' needs for fast and accurate chemistry results," said Robert Grieve, Heska's Chairman and Chief Executive Officer. "Heska's dedicated pursuit to bringing the most advanced diagnostics to the veterinary industry is resolute."

About Heska

Heska Corporation (NASDAQ: HSKA) sells advanced veterinary diagnostic and other specialty veterinary products. Heska's state-of-the-art offerings to its customers include diagnostic instruments and supplies as well as single use, point-of-care tests, pharmaceuticals and vaccines. The company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled customer support to veterinarians. For further information on Heska and its products, visit the company's website at www.heska.com.

Forward-Looking Statements

This announcement contains forward-looking statements regarding Heska's future operations. These statements are based on current expectations and are subject to a number of risks and uncertainties. Investors should note that these statements are based on current plans, which may not be fulfilled as expected and may not have the positive impact even if fulfilled as expected. In addition, factors that could affect the business and financial results of Heska generally include the following: uncertainties surrounding recently launched products, including Heska's ability to successfully commercialize such products; risks regarding Heska's ability to successfully market, sell and distribute its products in an economically sustainable manner; competition, including uncertainties regarding the impact of new products competitors have recently launched or may launch in the future; risks regarding Heska's reliance on third-party suppliers, which is substantial and could have significant negative consequences if Heska were to lose exclusive rights or access to a product due to a supplier decision or for other reasons; uncertainties related to the loss of access to products from Abbott Point of Care Inc. after November 1, 2009, which represent approximately 18% of Heska's revenue for the year ended September 30, 2009; uncertainties regarding Heska's reliance on third parties to whom Heska has granted substantial marketing rights to certain of Heska's existing products and whom may be large Heska customers; uncertainties regarding Heska's ability to generate profits and positive cash flow in future periods; uncertainties related to Heska's ability to maintain its listing on the Nasdaq Capital Market; risks related to Heska's reliance on third parties to properly and timely complete certain research and development activities; and the risks set forth in Heska's filings and future filings with the Securities and Exchange Commission, including those set forth in Heska's Annual Report on Form 10-K for the year ended December 31, 2008 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2009.

SOURCE Heska Corporation


'/>"/>
SOURCE Heska Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Webcast Alert: Heska Announces Second Quarter 2009 Earnings Conference Call Webcast
2. Heska Announces Q109 Results
3. Webcast Alert: Heska Corporations Annual Meeting of Stockholders Webcast
4. Heska Announces Q4 and Annual 2008 Results
5. Webcast Alert: Heska Announces Fourth Quarter and Year-End 2008 Earnings Conference Call Webcast
6. Heska to Present at New York Society of Security Analysts 12th Annual Biotech and Specialty Pharma Conference
7. Heska Announces Q3 2008 Results
8. Webcast Alert: Heska Announces Third Quarter 2008 Earnings Conference Call Webcast
9. Deloitte Names Heska Corporation to Colorado Technology Fast 50
10. Webcast Alert: Heska Announces First Quarter 2008 Earnings Conference Call Webcast
11. Webcast Alert: Heska Corporations Annual Meeting of Stockholders Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased ... Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network ... experience in dermatology, skin cancer , and more. She graduated from the University ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and ... the rise, say researchers presenting their work at the American Orthopaedic Society ... combination of evaluating the patterns of change in concussion symptom presentation, diagnostic tools ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) is ... rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem ... With such a challenging diagnosis that requires immediate action, patients and caregivers ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing ... specially designed to accommodate patients with a wide range of ailments or special needs, ... has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... 11, 2017  The global market for liquid biopsy ... $394.1 million in 2016.  Although in early stages, the ... in particular as a result of the gradual shift ... recent introduction of a significant number of new liquid ... of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
Breaking Medicine Technology: